Page 2 - Omp360 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Omp360. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Omp360 Today - Breaking & Trending Today
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse events demonstrate ....
London, UK - 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental ....
(0) LONDON, June 03, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) ( COMPASS ), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has reported further results from a phase I study showing that its COMP360 psilocybin had no clinically-relevant negative effect on cognitive function, when administered to healthy adult volunteers with support from specially trained therapists. The data) from the randomised, double-blind, placebo-controlled, phase I trial conducted at King s College London, will be presented today at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, by Dr James Rucker, Consultant Psychiatrist and Senior Clinical Lecturer in Psychopharmacology at King s College London s Institute of Psychiatry, Psychology and Neuroscience (IoPPN). Initial results from the study were published in December 2019. The results published today present a more in-depth analysis of c ....
(0) Study concludes that psilocybin findings should be explored further in larger studies London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASS s COMP360 psilocybin. This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a selective serotonin reuptake inhibitor (SSRI), for MDD. The study included 59 participants; 30 were randomly assigned to the psilocybin arm, and 29 to the escitalopram arm. Participants in the psilocybin arm received two doses of 25mg psilocybin three weeks apart, with psychological support delivered prior to, during and after each psilocybin administration, plus six weeks of ....